Insight

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma

my.clevelandclinic.org

Dec 20, 2024, 10:22

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma

Jame Abraham,Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on X:

“Bispecific Antibody Glotiftamab Combination with Chemoimmunotherapy Safe and Effective for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy.”

More posts featuring Jame Abraham.

Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.

Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).

bispecific antibody Cancer research cancer treatment chemoimmunotherapy Cleveland Clinic Diffuse Large B-Cell Lymphoma Glotiftamab Jame Abraham Oncology relapsed cancer

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage